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Mutations in the key rod phototransduction enzyme phosphodiesterase 6 (PDE6) are known to cause
recessive retinitis pigmentosa in humans. Mouse models of mutant PDE6 represent a common approach
to understanding the mechanisms of visual disorders related to PDE6 defects. Mutation N605S in the
PDE6B subunit is linked to atypical retinal degeneration 3 (atrd3) in mice. We examined PDE6 in atrd3
mice and an atrd3 mutant counterpart of human cone PDE6C expressed in rods of transgenic Xenopus
laevis. These animal models revealed remarkably different phenotypes. In contrast to dramatic downreg-
ulation of the mutant rod PDE6 protein and activity levels in mice, expression and localization of the cone
PDE6C in X. laeviswere essentially unaffected by this mutation. Examination of the PDE6B mRNA in atrd3
retina showed that the mutation-carrying exon 14 was spliced-out in the majority of the transcript. Thus,
retinal degeneration in atrd3 mice is caused by low levels of PDE6 protein due to defective processing of
PDE6B pre-mRNA rather than by deleterious effects of the N605S mutation on PDE6 folding, stability or
function.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Rod and cone photoreceptor cells respond to light stimuli by
activating phosphodiesterase-6 (PDE6) that hydrolyze cGMP there-
by modulating cGMP-gated channels in the plasma membrane
(Burns & Arshavsky, 2005; Fu & Yau, 2007; Lamb & Pugh, 2006).
Rod PDE6 is a heterotetramer composed of two catalytic subunits,
PDE6A and PDE6B, and two copies of the small inhibitory Pc sub-
unit. Cone PDE6 is highly homologous to the rod enzyme and is a
tetramer comprised of two identical catalytic subunits PDE6C
and two copies of a cone-speciﬁc Pc subunit (reviewed in Zhang
and Cote (2005)). Mutations in the PDE6A and PDE6B genes are
responsible for a signiﬁcant fraction of cases of recessive retinitis
pigmentosa (RP), a common disease of progressive photoreceptor
degeneration leading to loss of vision. In addition, mutations in
rod PDE6 may lead to a non-progressive night blindness (Dryja
et al., 1999; Huang et al., 1995; McLaughlin et al., 1993). The
PDE6B H258N mutation was reported in the Rambusch form of
dominant stationary night blindness (Gal et al., 1994). Recently,ll rights reserved.
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v), nikolai-artemyev@uiowa.PDE6Cmutations have been found in human patients with progres-
sive cone dystrophy and achromatopsia (Chang et al., 2009;
Thiadens et al., 2009). These disorders of cone function are charac-
terized by low visual acuity and lack of color discrimination.
Certain pathogenic PDE6 alterations such as nonsense mutations,
frame-shifts, or splicing defects apparently result in complete loss
of PDE6 function. Often PDE6 mutations in RP and achromatopsia
are missense mutations leading to substitutions of conserved resi-
dues within the regulatory GAF domains or the catalytic domains.
The mechanisms of such PDE6 mutations are not understood and
may include loss of PDE6 function due to protein folding defects,
deﬁcient transport of PDE6 to the site of phototransduction, or
abnormal function of the enzyme.
Despite numerous efforts, heterologous expression of PDE6 has
not been attained. Thus, characterization of animal models has
been the main approach to understanding the mechanisms of hu-
man visual disorders caused by mutations of the PDE6 catalytic
subunits. Mouse models with spontaneous or chemically-induced
mutations in PDE6B and, more recently, PDE6A and PDE6C have
been identiﬁed (Bowes et al., 1990; Chang et al., 2007, 2009; Hart
et al., 2005; Sakamoto et al., 2009; Pittler & Baehr, 1991; Thaung
et al., 2002). The rd1 mouse is a classical loss-of-function model
with disruption of the PDE6B gene causing elevation of cGMP levels
and rapid retinal degeneration (Bowes et al., 1990; Farber & Lolley,
1974; Pittler & Baehr, 1991). Similarly, a spontaneous disruption of
the PDE6C gene in the cpﬂ1 mutant mouse causes rapid degenera-
tion of cones (Chang et al., 2009). However, mouse models with
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majority of PDE6-related cases of RP. The progression of photore-
ceptor degeneration in these animal models is slower than in rd1
mice, theoretically allowing examination of biochemical outcomes
of PDE6 mutations. Furthermore, a slow progression of retinal
degeneration in mutant mice potentially indicates change of func-
tion as opposed to loss-of-function mutations.
Three recessive PDE6B alleles causing a relatively slow onset of
retinal degeneration were originally selected in a screen for novel
N-ethyl-N-nitrosourea-induced mutations that lead to vision dis-
orders in the mouse (Hart et al., 2005; Thaung et al., 2002). The
mutant alleles were termed atrd1–atrd3 for atypical retinal degen-
eration (Thaung et al., 2002). The atrd3 allele appeared particularly
interesting (Barren et al., 2009; Hart et al., 2005). This allele was
originally reported to carry the N606S mutation (Hart et al.,
2005). However, our sequencing of genomic DNA obtained from
atrd3 mice indicated a N605S mutation, which is in agreement
with the current annotation of the mutant allele at the Mouse
Genome Informatics database (ID: MGI: 2178316). The position
corresponding to Asn605 in mouse PDE6B is not absolutely con-
served among PDEs. PDE1 and PDE3 contain a Thr residue, whereas
PDE4 and PDE10 contain a Ser residue at this position, which is
analogous to the Asn? Ser substitution in atrd3 mice. Moreover,
the atomic structure of the chimeric PDE5/PDE6 catalytic domain
complexed with the inhibitory peptide of Pc revealed that the
Asn residue contributes to the Pc-binding site, suggesting a poten-
tial functional defect of the atrd3 mutant (Barren et al., 2009). To
investigate the mechanism of the PDE6B N605S mutation in retinal
degeneration, we examined PDE6 in atrd3 mice. In addition, we
generated transgenic X. laevis expressing an atrd3 counterpart of
EGFP-fused human PDE6C in rods, PDE6C-N610S. Surprisingly,
the two animal models revealed strikingly different phenotypes.
In mouse atrd3 retina, levels of PDE6B expression and total PDE6
activity were markedly downregulated, whereas in frog retina,
expression and localization of EGFP-PDE6C were essentially unaf-
fected by this mutation. The difference in the phenotypes is recon-
ciled by the ﬁnding of the abnormal PDE6B pre-mRNA splicing in
mutant mice leading to very low expression levels of PDE6.2. Methods
2.1. Animals
Homozygous atrd3+/+ female mice were obtained from the Mary
Lyon Center (England). The mice were mated with wild-type mice
(C57Bl/6) to obtain heterozygous atrd3+/ mice, which were subse-
quently bred to obtain homozygous atrd3+/+ mice. Mice were gen-
otyped by PCR-ampliﬁcation and DNA sequencing of the mutant
PDE6B region. Transgenic X. laevis expressing EGFP-PDE6C in rods
were generated by the method of sperm nuclear transplantation
as previously described (Muradov et al., 2009). The N610S muta-
tion was introduced by PCR-directed mutagenesis into the PDE6C
DNA sequence which was then cloned into the pXOP(508/
+41)EGFP vector using NotI and XmaI sites. The construct sequence
was conﬁrmed by automated DNA sequencing. X. laevis tadpoles
expressing EGFP-PDE6C-N610S were obtained similarly as
described for EGFP-PDE6C (Muradov et al., 2009). All experimental
procedures involving the use of mice and frogs were carried out in
accordance with the protocol approved by the University of Iowa
Animal Care and Use Committee.2.2. Immunoﬂuorescence
Mouse eyeballs were enucleated and the corneas were perfo-
rated with a 21 gauge needle, ﬁxed in PBS with 4% formaldehydefor 1 h and cut in half. The cornea and lens were removed, and
the eyecups were submersed in a 30% sucrose solution in PBS for
5 h at 4 C. The eyecups were then embedded in tissue freezing
medium (Triangle Biomedical Sciences) and frozen on dry ice.
Radial sectioning (10 lm) of the retina was performed using a
cryomicrotome HM 505E. Retinal cryosections were air-dried and
kept at 80 C. The sections were warmed up to room temperature
and incubated in PBS/0.1% Triton X-100 for 30 min. Labeling with
anti-rhodopsin 1D4 monoclonal antibody (1:200) (Santa Cruz
Biotech), rabbit anti-PDE6B PA1-722 (1:1000) (Thermo Scientiﬁc)
antibody, anti-PDE6 MOE antibody (1:1000) (CytoSignal), or anti-
Pc-(63–87) antibody (1:1000; gift of Dr. R. Cote, University of
New Hampshire) was performed in PBS containing 3% BSA for
1–2 h at 25 C. Following 1-h incubation with goat anti-mouse
AlexaFluor 488, goat anti-rabbit AlexaFluor 488, or goat anti-rabbit
AlexaFluor 568 secondary antibodies (Invitrogen) (1:1000), the
sections were visualized using a Zeiss LSM 510 confocal micro-
scope. In situ cell death detection kit, TMR red (Roche), was used
for TUNEL staining of retina cryosections according to manufac-
turer’ protocol. The sections were counterstained with To-Pro3
(Invitrogen).
2.3. EGFP-ﬂuorescence
At about stage 48–50, retinas from transgenic tadpoles were
dissected into small pieces in a Ringer’s buffer and the EGFP-
ﬂuorescence in living photoreceptor cells was imaged using
LSM510 (Zeiss).
2.4. PDE6 extraction, immunoblotting, immunoprecipitation, and
PDE6 activity assays
To determine the total levels of expression of PDE6 subunits, ret-
inas of P10 atrd3+/+ andwild-type (C57Bl/6)micewerehomogenized
in 10 mM Tris–HCl buffer pH 7.5 containing 1 mM 2-mercap-
toethanol and 1% Triton X-100 (25 ll/retina) and centrifuged at
16,000g for 10 min. The supernatants were separated by SDS PAGE
and analyzed byWestern blottingwith anti-PDE6 antibody 63F (gift
of Dr. R. Cote, University of New Hampshire) and anti-PDE6B PA1-
722 (Thermo Scientiﬁc). For PDE6 activity analyses, P10 atrd3+/+
and WT retinas were homogenized with a pestle in an Eppendorf
tube in 20 mM Tris–HCl buffer (pH 7.5) containing 120 mM NaCl,
1 mM MgSO4, 1 mM 2-mercaptoethanol, and complete protease
inhibitor cocktail (Roche) (30 ll/retina). Aliquots of retina homoge-
nateswereused formeasurementsof the total levels of PDE6activity
following trypsin-treatment (30 lg retina protein/2 lg trypsin,
0–20 min, 0 C, terminated with 10 SBTI). 5-min treatment maxi-
mally activated PDE6 activity. The rest of the homogenates were
centrifuged (20,000g, 20 min, 4 C), and the resulting pellet was
re-suspended in hypotonic 10 mM Tris–HCl (pH 7.5) buffer (15 or
30 ll/retina) containing 1 mM b-mercaptoethanol and complete
protease inhibitor cocktail. The PDE6-containing hypotonic super-
natants (70,000g, 60 min, 4 C) were used immediately or stored at
80 C. Samples of PDE6 extracts containing equal amounts of func-
tional PDE6 were used for immunoprecipitation. Hypotonic PDE6
extract from 20 to 25 atrd3+/+ retinas contained as much functional
PDE6 as that from 1WT retina as determined by PDE6 activity after
trypsin-treatment. Dynabeads with Protein G (30 ll, 30 mg/ml)
(Invitrogen)werewashedwith 20 mMTris–HCl (pH 7.5) buffer con-
taining 500 mM NaCl, 1 mMMgSO4, and 1 mM 2-mercaptoethanol
(buffer A) and incubatedwith anti-PDE6B PA1-722 (5 lg) for 60 min
at 25 C. The beads were washed from unbound proteins two times
with buffer A, followed by the addition of PDE6 extracts from WT,
Nrl/ or atrd3+/+ retinas and incubation with rotation for 3 h at
4 C. The beadswere thenwashed four timeswith buffer A, one time
with buffer A minus NaCl, and ﬁnally one time with buffer A. Resins
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20 mM Tris–HCl (pH 7.5) buffer containing 100 mM NaCl, 10 mM
MgSO4, and 1 mM 2-mercaptoethanol and aliquots of suspension
(5 ll out total 750 ll) were assayed for PDE activity after activation
with trypsin (0.5 lg trypsin, 5 min, 20 C, terminated with 10
SBTI). Immunoprecipitated proteins from the remaining samples
of resin were eluted with SDS-sample buffer and analyzed by
Westernblotting using the PDE6MOEantibody (CytoSignal). Immu-
noblotting of retinal extracts from transgenic EGFP-PDE6C and
EGFP-PDE6C-N610S retinaswith anti-GFP B-2monoclonal antibody
(Santa Cruz Biotech) and anti-PDE6MOE antibody (CytoSignal) was
performed as previously described (Muradov, Boyd, & Artemyev,
2010; Muradov et al., 2009).2.5. RNA isolation and RT-PCR
Total RNA was isolated from six P10 retinas of each C57Bl/6
(WT) and atrd3 mice using the TRI reagent according to Molecular
Research Center protocol. RT-PCR ampliﬁcations were performed
on both RNA samples using SuperScript III One-Step RT-PCR kit
(Invitrogen) and three pairs of primers designed to generate over-
lapping products covering the full-length PDE6B cDNA: 1st pair –
(24)–(1) and 834–866, 2nd pair – 794–823 and 1854–1886,
and 3rd pair – 1622–1655 and 2575–2606 (30-UTR).2.6. Analysis of PDE6B transcripts by real-time PCR
First-strand cDNAs were synthesized on total RNAs from p10
C57Bl/6 (WT) and atrd3 retinas using PDE6B exon 15-speciﬁc pri-
mer and SuperScript III Reverse transcriptase (Invitrogen). Four se-
rial dilutions of these cDNA samples (each in triplicate) were used
as templates in real time PCR ampliﬁcations of 130 bp products
from exons 12 and 14 with an Applied Biosystems 7000 Real-Time
PCR System and iQ™ SYBR Green Supermix (Bio-Rad) as per the
manufacturers’ protocols. The total levels of PDE6B transcripts in
control and atrd3 samples were normalized using the threshold cy-
cle values (CT) for the exon 12 PCR product. The level of exon 14
skipping in atrd3 retina was determined based on the CT values
for exon 14.Fig. 1. Time-course of apoptosis in atrd3+/+ retinas. Retina cryosections from heterozygo
cell death detection kit TMR red (Roche), and counterstained with To-Pro3 (blue). Scale2.7. Genomic DNA analysis
Genomic DNAs of WT and atrd3mice were isolated from mouse
tail clips. PCR products from genomic DNA covering PDE6B exons
13–15 and ﬂanking introns were sequenced. No differences except
the Asn? Ser (A to G) mutation in exon 14 were found between
the WT and atrd3 samples.3. Results
3.1. Retinal degeneration in atrd3 mice
To identify an appropriate time point for examination of PDE6 in
atrd3 mice we determined the time-course for the onset of retinal
degeneration. The TUNEL staining of retina sections from homozy-
gous atrd3 mice indicated that the outer nuclear layer (ONL) of
atrd3+/+ mice is normal at postnatal day 10 (P10), but apoptotic
nuclei appear by P14 (Fig. 1). The photoreceptor cell death led to
a twofold reduction in the thickness of ONL by P19, and only
two cell layers were left in the ONL by P30 in atrd3 mice (Fig. 1).
Heterozygous atrd3+/ mice displayed normal retinal morphology
with no signs of retinal degeneration (Fig. 1) and served as controls
in the immunoﬂuorescence analyses. The immunoﬂuorescence
staining of rhodopsin showed that the OS layer is well-deﬁned in
both heterozygous and homozygous atrd3 mice at P10. However,
OS in homozygous atrd3mice deteriorated at P19 and disintegrated
at P30 (Fig. 2). Thus, P10 retinas were used in the study to avoid
potential inﬂuence of apoptosis on PDE6 expression and activity.3.2. Expression and activity of PDE6 in atrd3 retinas
The total levels of expression of PDE6 subunits were probed in
P10 retina extracts of atrd3 and control mice using the PDE6 anti-
body 63F that recognizes rod PDE6AB and cone PDE6C equally well
(Muradov, Boyd, & Artemyev, 2010). Western blotting using this
antibody revealed a double band of 88 and 90 kDa corresponding
to the wild-type PDE6 in WT (C57Bl/6) retina and only a single
90 kDa band in atrd3 retina (Fig. 3). The 90 kDa signal in the atrd3
retina was comparable to that in controls. The re-blot analysis with
PDE6B-speciﬁc antibody PA1-722 (ABR) showed a speciﬁc staining
of the 88 kDa band in control retina and the absence of the corre-
sponding band in the atrd3+/+ retina (Fig. 3). A weak signal seen inus atrd3+/ (control) and homozygous atrd3+/+ mice were TUNEL-stained (red) using
bar – 10 lm.
Fig. 2. Rhodopsin immunoﬂuorescence in atrd3+/+ retinas. Retina cryosections of atrd3+/ (control) and atrd3+/+ were labeled with the rhodopsin 1D4 antibody followed by
staining with goat anti-mouse AlexaFluor 488 secondary antibody. Scale bar – 10 lm.
Fig. 3. Expression of PDE6 subunits in wild-type and atrd3+/+ mouse retina. Samples
of Triton X-100 (1%) extracts each corresponding to one P10 retina were analyzed
by Western blotting with anti-PDE6 antibody 63F. The blot was then stripped and
re-probed with anti-PDE6B PA1-722 antibody (Thermo Scientiﬁc). Samples of
hypotonic retina extracts corresponding to one-half of P10 WT (C57Bl/6) retina, one
Nrl/ retina or one atrd3+/ retina were analyzed by Western blotting with anti-Pc
antibody.
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the PDE6B band. This signal is apparently not PDE6B-speciﬁc. Thus,
the protein level of PDE6B is markedly reduced, whereas the level
of PDE6A is seemingly unchanged in atrd3+/+ retina. The 90 kDa
band may include PDE6C since it cannot be distinguished from
PDE6A with the 63F antibody. Immunoblotting of control and
atrd3+/+ retinal extracts with Pc-speciﬁc antibody showed that Pc
is also markedly reduced in the mutant retina (Fig. 3). In agreement
with the immunoblotting results, immunoﬂuorescence analysis
using the PDE6B antibody PA1-722 showed robust staining of OS
layer of P10–P30 control retina sections but no PDE6B staining
using atrd3+/+ retina sections (Fig. 4). Antibody 63F is not suitable
for immunoﬂuorescence analysis. However, MOE antibody that
recognizes both PDE6A and PDE6B did reveal the presence of
greatly diminished levels of PDE6, presumably PDE6A, in the pho-
toreceptor layer of atrd3+/+ retina (Fig. 5A). A fraction of PDE6 ap-
pears to be mislocalized to the rod inner compartments. The
PDE6A immunoﬂuorescence signal in atrd3+/+ retina is weaker than
expected based on the PDE6A level detected by antibody 63F
(Fig. 3). This may be due to misfolding of PDE6A. Immunoﬂuores-
cence analysis using Pc-speciﬁc antibody revealed Pc-staining in
the ROS layer of control P10 retina and no Pc-signal in the P10
atrd3+/+ retina, conﬁrming a dramatic reduction in the level of
the inhibitory subunit (Fig. 5B).
The total levels of PDE6 activity were measured in P10 retina
homogenates following trypsin treatment. Trypsin fully activates
PDE6 catalytic subunits by removing the inhibitory Pc subunits,and the trypsin-activated PDE6 activity is a good measure of total
functional PDE6. The PDE assays demonstrated that PDE6 activity
is reduced by 18-fold in atrd3+/+ retinas (0.060 ± 0.005 nmol
cGMP/lg protein/min) compared to control retinas (1.1 ± 0.1 nmol
cGMP/lg protein/min). The dramatic reduction in total PDE6 activ-
ity raises the question of what fraction of the residual PDE6 activity
can be attributed to cone PDE6C. To address this question, we per-
formed immunoprecipitations of PDE6 from WT (C57Bl/6) and
atrd3+/+ retinas using PDE6B PA1-722 antibody. Control immuno-
precipitations were also carried out using Nrl/ retina extracts.
Nrl/ retinas predominantly express cone PDE6C as well as trace
amounts of rod PDE6AB (Kolandaivelu, Chang, & Ramamurthy,
2011). The inputs into IP experiments were equalized by PDE6
activity determined in aliquots after activation with trypsin. Thus,
the inputs contained equal amounts of combined functional PDE6
from both rods and cones. Immunoprecipitated proteins were ana-
lyzed for PDE6 activity and byWestern blottingwithMOE antibody.
The PDE6 activity immunoprecipitated from control retinas was
12-fold greater than that from Nrl/ retinas and 7-fold greater
than that from atrd3 retinas. All PDE6 enzymes in Nrl/ retinas
are predicted to be functional. Thus, the low-level immunoprecipi-
tation of PDE6 activity from Nrl/ retinas is consistent with the re-
ported presence of up to 10% of rod PDE6 in Nrl/ retina
(Kolandaivelu, Chang, & Ramamurthy, 2011). This also indicates
the speciﬁcity of rod PDE6 precipitation by PDE6B PA1-722 anti-
body. In agreement with the immunoprecipitation levels of PDE6
activity, the immunoblot analysis with MOE antibody showed
robust PDE6 signal in control IP samples, a very faint band in the
atrd3 IP samples, and no detectable signal in the Nrl/ IP samples
(Fig. 6). Although these IP experiments are not quantitative, they
clearly suggest that functional rod PDE6 represents only a fraction
of total PDE6 activity in the atrd3+/+ retinawith the remaining activ-
ity apparently originating from cone PDE6.
3.3. Transgenic X. laevis model of atrd3 mutant counterpart of cone
PDE6C
The N610S mutation (human PDE6C counterpart of N605S in
mouse PDE6B) was introduced by PCR-directed mutagenesis into
the PDE6C DNA sequence which was then cloned into the
pXOP(508/+41)EGFP vector. Transgenic X. laevis expressing
EGFP-PDE6C-N610S have been generated by the method of sperm
Fig. 4. PDE6B immunoﬂuorescence is absent in atrd3+/+ retinas. Retina cryosections of control and atrd3+/+ were labeled with the PDE6B-speciﬁc antibody PA1-722 followed
by staining with goat anti-rabbit AlexaFluor 488 secondary antibody.
Fig. 6. Immunoprecipitation of PDE6 from WT, Nrl/ and atrd3+/+ retinas with
PDE6B-speciﬁc antibodies. Immunoprecipitations were carried out using hypotonic
retina extracts and Protein G dynabeads with pre-bound anti-PDE6B PA1-722
antibodies. The inputs into IP experiments were equalized by the levels of trypsin-
activated PDE6 activity. Aliquots of re-suspended beads with immunoprecipitated
proteins were treated with trypsin and analyzed for PDE6 activity (A). Remaining
aliquots were analyzed by immunoblotting with anti-PDE6 MOE antibody (B).
Fig. 5. Combined immunoﬂuorescence of PDE6 subunits is markedly reduced in P10 atrd3+/+ retinas. Retina cryosections of control and atrd3+/+ were labeled with (A) the
PDE6 MOE antibody that reacts with all PDE6 subunits (PDE6A, B, C, and Pc) or (B) the Pc-speciﬁc antibody. Sections were stained with goat anti-rabbit AlexaFluor 568 (A), or
goat anti-rabbit AlexaFluor 488 secondary antibodies (B). Scale bar – 10 lm.
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described for EGFP-PDE6C (Muradov, Boyd, & Artemyev, 2010;
Muradov et al., 2009). The EGFP-ﬂuorescence imaging in living
photoreceptor cells showed that EGFP-PDE6C-N610S is expressed
and properly localized to the rod OS in transgenic X. laevis(Fig. 7A). The striated pattern of PDE6C-N610S EGFP-ﬂuorescence
is similar to the previously described pattern of EGFP-PDE6C
(Muradov et al., 2009). This pattern is consistent with association
of PDE6C-N610S with the rims and incisures of photoreceptor
disks.
The immunoblot analysis of the retinal extracts with anti-GFP
antibody indicated that the average levels of EGFP-PDE6C-N610S
expression are comparable to the levels of EGFP-PDE6C and well
below the endogenous frog PDE6 (Fig. 7B).3.4. Defective PDE6B pre-mRNA processing in atrd3 retina
Transgenic X. laevis were generated using PDE6C cDNA con-
struct, and therefore EGFP-PDE6C expression in the frog model
does not depend on pre-mRNA processing. The contrast between
markedly reduced levels of PDE6 in atrd3 mice and unimpaired
expression of PDE6C-N610S in transgenic X. laevis prompted us
to examine PDE6B mRNA sequence in mutant mice. RT-PCR ampli-
ﬁcation of the PDE6B region corresponding to nucleotides 794–
1886 from atrd3 mRNA yielded the product that was 100-bp
shorter than those from WT mRNA (Fig. 8A). Sequencing of the
product revealed deletion of exon 14 (nt 1722–1832) from the
transcript (Fig. 8B). This deletion introduces a frame shift and a
premature stop codon downstream of exon 13 (Fig. 8B). Consistent
Fig. 7. Expression of EGFP-PDE6C in transgenic X. laevis rods. (A) EGFP-ﬂuorescence
in living photoreceptor cells expressing EGFP-PDE6C-N610S. ROS – rod outer
segment, RIS – rod inner segment. (B) Immunoblotting of retinal extracts from
transgenic EGFP-PDE6C and EGFP-PDE6C-N610S retinas with anti-GFP B-2 mono-
clonal antibody (Santa Cruz Biotech) and anti-PDE6 MOE antibody (CytoSignal).
A
B
Fig. 8. Exon 14 skipping in PDE6B mRNA in atrd3 mice. (A) Regions corresponding
to nucleotides – 24–866 (left), 794–1886 (middle), and 1622–2606 (right) of PDE6B
mRNA were RT-PCR ampliﬁed from WT and atrd3 RNA samples. The 794–1886 and
1622–2606 products are 100-bp shorter for the atrd3 samples compared to WT.
(B) Sequencing of the RT-PCR product 794–1886 from WT mice showed correct
exon splicing. Residue Asn605 (AAC) mutated to Ser (AGC) in atrd3 mice is
underlined. Exon 14 is deleted from the atrd3 transcript. This deletion introduces a
frame shift and a premature downstream stop codon.
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fy nucleotides 1622–2606 of the PDE6B transcript also yielded
shorter product as well as additional larger than predicted prod-
ucts (Fig. 8A). The latter products are likely to contain additionalintronic sequences downstream of exon 14. In order to determine
if the defective splicing of the PDE6B mRNA is caused by a second-
site mutation, we sequenced a region of genomic DNA from atrd3
mice covering exons 13–15 and ﬂanking introns. No additional
mutations were found. Real-time PCR analysis indicated that exon
14 is missing in 80% of PDE6B transcripts in atrd3 retina. We
further analyzed the atrd3 PDE6B transcripts containing exon 14
by PCR with 50 primer from exon 14 and 30-primer from the 30-
UTR, which produced four discrete products. Sequencing indicated
that one of these products represented correctly spliced PDE6B
mRNA, whereas the remaining products contained one or more in-
trons after exons 14, 15, 17, and 18 (not shown). Thus, we esti-
mated that the fraction of the correctly spliced PDE6B mRNA in
atrd3 retina is less than 5%.4. Discussion
Mouse models with mutant rod PDE6 characterized to date
present stark limitations for PDE6 biochemical analyses. Most of
the reported mutations are random rather than targeted mutations
that correspond to disease alleles in humans. Almost all mouse
models with homozygous mutations in PDE6A or PDE6B revealed
dramatic reductions in the protein level and activity of rod PDE6
(Chang et al., 2007; Sakamoto et al., 2009). The markedly reduced
levels of PDE6AB make it very difﬁcult to distinguish the residual
mutant rod PDE6 activity from the activity of cone PDE6C. Further-
more, the potential inﬂuence of processes leading to retinal degen-
eration on the properties of mutant PDE6 cannot be ruled out. We
embarked on characterization of PDE6 in atrd3 mice with the mis-
sense N605S mutation in PDE6B based on indications that this
mutation may alter PDE6 function rather than grossly affect the
folding and/or assembly of rod PDE6. The structure of the chimeric
PDE5/PDE6 catalytic domain shows that the H-loop Asn residue, a
counterpart of PDE6BAsn605, makes two important contacts, one
intramolecular contact with the M-loop and one intermolecular
contact with Pc (Barren et al., 2009). The intramolecular bond
may inﬂuence folding of PDE6, whereas the intermolecular contact
may be important for the PDE6-Pc interaction. In the mutant PDE6
molecule, the Ser side chain would be able to maintain either one
of the interactions, but not both contacts simultaneously (Barren
et al., 2009). However, the Asn? Ser mutation did not affect the
expression levels and catalytic properties of the chimeric PDE5/
PDE6 catalytic domain, and it only modestly reduced the inhibition
of its activity by Pc (Barren et al., 2009). Unexpectedly, the analysis
of PDE6 in P10 atrd3 retina showed a severe reduction of PDE6B.
PDE6B is not detected by PDE6B-speciﬁc antibody using immuno-
blotting of atrd3 retina proteins or immunoﬂuorescence analysis of
retina sections. Interestingly, the levels of PDE6A in mutant retinas
are comparable to those in control mice, suggesting that PDE6A is
expressed in the absence of PDE6B. Nonetheless, PDE6A in atrd3
retinas is apparently catalytically inactive, since the overall PDE6
activity in the retina is reduced by 18-fold in comparison to con-
trol retinas. Similarly, nonfunctional PDE6A protein is expressed in
the absence of PDE6B in rd1 retina (Tsang et al., 1996). Immuno-
precipitation of rod PDE6 from atrd3 retina extracts indicated that
rod PDE6 activity constitutes only a fraction of the total PDE6
activity in mutant mice. Thus, prior to the onset of retinal degener-
ation, the degree of downregulation of rod PDE6 in atrd3 mice is
likely to be signiﬁcantly greater than 18-fold. The rate of retinal
degeneration in atrd3 mice is slower than that in rd1 or Aipl1/
mice which have no functional rod PDE6 at any point of postnatal
development (Lee et al., 1988; Ramamurthy et al., 2004; Tsang
et al., 1996). The time course of rod cell death in atrd3mice appears
to be slightly faster compared to the progression of retinal degen-
eration in rd10 mice with the R560C mutation in PDE6B or PDE6A
H. Muradov et al. / Vision Research 57 (2012) 1–8 7mutant mice with the D670G substitution (Chang et al., 2007;
Sakamoto et al., 2009). Both of these mouse models show signiﬁ-
cant reductions in PDE6 protein levels and/or activity (Chang
et al., 2007; Sakamoto et al., 2009). Thus, a correlation apparently
exists between the levels of functional PDE6 protein and the sever-
ity of retinal degeneration.
Given the limitations of mouse models, new approaches to
analysis of pathogenic PDE6 mutants are necessary. Recently, we
demonstrated the utility of transgenic X. laevis for expression and
characterization of recombinant PDE6C in rods (Muradov, Boyd,
& Artemyev, 2010; Muradov et al., 2009). The transgenic frog sys-
tem offers several advantages. It allows imaging of EGFP-PDE6C
expression and localization in living rods. Also, the potential inﬂu-
ence of processes leading to retinal degeneration in homozygous
mutant PDE6 mice can be avoided in the Xenopus model due to
the presence of native frog rod PDE6. Finally, if a functional mutant
rod PDE6AB is present in a mouse model, it is difﬁcult to ascertain
the activity of the mutant catalytic subunit in a heterodimer with
the wild-type catalytic subunit. The X. laevis model of artd3 muta-
tion yielded a very different phenotype. The PDE6C-N610S mutant
was correctly targeted to the rod OS in the retina of transgenic
X. laevis and apparently concentrated at the rims and incisures of
photoreceptor disks, just as PDE6C. The average levels of protein
expression of PDE6C-N610S were similar to those of PDE6C. Hypo-
thetically, molecular differences between rod and cone PDE6 could
have accounted for the differences in the phenotypes of the mouse
and frog models. However, the site of atrd3mutation, the H-loop of
PDE6, is highly conserved among cone and rod PDE6 catalytic sub-
units, arguing against such a possibility. Transgenic EGFP-PDE6C
expression in the frog model does not involve pre-mRNA process-
ing. Therefore, we sequenced and analyzed PDE6B mRNA from P10
atrd3 retinas. This analysis demonstrated that 80% of the tran-
script lacked exon 14 carrying the N605S mutation. Furthermore,
the predominant fraction of the remaining 20% transcript with
exon 14 contained downstream intronic sequences. Thus, retinal
degeneration in atrd3 mice is caused by defective processing of
PDE6B mRNA and resulting very low levels of PDE6 protein rather
than by effects of N605S mutation on the protein folding or
stability.
Increasing evidence suggests that exonic missense and silent
mutations can induce the splicing machinery to skip the mutant
exon (reviewed in Cartegni, Chew, and Krainer (2002)). About
one quarter of synonymous variations in exon 12 of the cystic
ﬁbrosis transmembrane conductance regulator (CFTR) gene result
in exon skipping and inactive CFTR protein (Pagani, Raponi, & Bar-
alle, 2005). Exonic mutations may affect exonic splicing enhancers
(ESEs) that have been recognized in many exons (Cartegni, Chew, &
Krainer, 2002). ESEs serve as binding sites for serine/arginine-rich
(SR) protein splicing factors. For instance, a predicted ESE disrup-
tion by a single silent mutation in the survival of motor neuron 1
gene leads to the skipping of exon 7 and causes spinal muscular
atrophy (Cartegni & Krainer, 2002; Lorson, Hahnen, Androphy, &
Wirth, 1999); Analysis of the mouse PDE6B exon 14 sequence
using ESEﬁnder 3.0 software (Smith et al., 2006) reveals the pres-
ence of several sites for SR proteins SF2/ASF and SC35. The As-
n(AAC)? Ser(AGC) mutation creates an additional SC35 site. The
mechanism for skipping PDE6B exon 14 in atrd3 mice remains to
be investigated. However, in a patient with growth hormone deﬁ-
ciency type II, mutation in ESE creates a functional SC35-binding
site that synergistically with the downstream SC35 site produced
pathological levels of exon 3 skipping. The effect of the additional
SC35 site was due to SC35 antagonistic action with SF2/ASF (Solis
et al., 2008). A signiﬁcant number of DNA polymorphisms were
found in the PDE6B gene in RP patients, although no cosegregation
analysis was performed (McLaughlin et al., 1995). The atrd3 model
highlights for the ﬁrst time the possibility that missense mutationsor SNPs in PDE6 genes can cause RP by aberrant splicing of
pre-mRNA.Acknowledgment
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